{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Squamous+Cell+Cancers+of+the+Head+and+Neck&page=20", "query": { "condition": "Squamous Cell Cancers of the Head and Neck", "page": 20 }, "page_size": 10 }, "pagination": { "page": 20, "page_size": 10, "total_count": 984, "total_pages": 99, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Squamous+Cell+Cancers+of+the+Head+and+Neck&page=21&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Squamous+Cell+Cancers+of+the+Head+and+Neck&page=19&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-15T18:21:22.395Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00573131", "title": "Efficacy and Safety of OncoGel™ Added to Chemotherapy and Radiation Before Surgery in Subjects With Esophageal Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Esophageal Cancer", "Adenocarcinoma of the Esophagus", "Squamous Cell Carcinoma" ], "interventions": [ { "name": "OncoGel (Paclitaxel gel)", "type": "DRUG" }, { "name": "cisplatin", "type": "DRUG" }, { "name": "5-FU", "type": "DRUG" }, { "name": "radiation therapy", "type": "RADIATION" }, { "name": "esophageal resection", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "RADIATION", "PROCEDURE" ], "sponsor": "Boston Scientific Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 137, "start_date": "2008-01", "completion_date": "2010-11", "has_results": true, "last_update_posted_date": "2022-06-22", "last_synced_at": "2026-10-15T18:21:22.395Z", "location_count": 8, "location_summary": "San Diego, California • Chicago, Illinois • Indianapolis, Indiana + 4 more", "locations": [ { "city": "San Diego", "state": "California" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Indianapolis", "state": "Indiana" }, { "city": "Kansas City", "state": "Kansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00573131" }, { "nct_id": "NCT05653882", "title": "A Study Evaluating AB248 Alone or in Combination With Pembrolizumab in Adult Patients With Solid Tumors", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Solid Tumor", "Non Small Cell Lung Cancer", "Melanoma", "Squamous Cell Carcinoma of Head and Neck", "Renal Cell Carcinoma" ], "interventions": [ { "name": "etakafusp alfa (AB248)", "type": "BIOLOGICAL" }, { "name": "pembrolizumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Asher Biotherapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 552, "start_date": "2023-01-04", "completion_date": "2027-05", "has_results": false, "last_update_posted_date": "2025-09-10", "last_synced_at": "2026-10-15T18:21:22.395Z", "location_count": 20, "location_summary": "Duarte, California • Los Angeles, California • San Diego, California + 15 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "New Haven", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT05653882" }, { "nct_id": "NCT00052429", "title": "High-Dose Radiation Therapy Plus Chemotherapy in Treating Patients With Advanced Nose or Throat Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Head and Neck Cancer" ], "interventions": [ { "name": "cisplatin", "type": "DRUG" }, { "name": "fluorouracil", "type": "DRUG" }, { "name": "adjuvant therapy", "type": "PROCEDURE" }, { "name": "radiation therapy", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "PROCEDURE", "RADIATION" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": 25, "start_date": "2002-09", "completion_date": "2010-11", "has_results": true, "last_update_posted_date": "2018-01-09", "last_synced_at": "2026-10-15T18:21:22.395Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00052429" }, { "nct_id": "NCT00720083", "title": "Chemotherapy and Radiation Therapy (RT) With or Without Vandetanib in Treating Patients With High-Risk Stage III or Stage IV Head and Neck Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Head and Neck Cancer" ], "interventions": [ { "name": "cisplatin", "type": "DRUG" }, { "name": "vandetanib", "type": "DRUG" }, { "name": "radiation therapy", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "Radiation Therapy Oncology Group", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 34, "start_date": "2008-11", "completion_date": "2011-08", "has_results": true, "last_update_posted_date": "2015-11-17", "last_synced_at": "2026-10-15T18:21:22.395Z", "location_count": 63, "location_summary": "Scottsdale, Arizona • Duarte, California • La Jolla, California + 52 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Duarte", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Sacramento", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00720083" }, { "nct_id": "NCT00064259", "title": "A Phase I/II Study of Oblimersen Plus Cisplatin and Fluorouracil in Gastric & Esophageal Junction Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Adenocarcinoma of the Esophagus", "Adenocarcinoma of the Gastroesophageal Junction", "Diffuse Adenocarcinoma of the Stomach", "Intestinal Adenocarcinoma of the Stomach", "Mixed Adenocarcinoma of the Stomach", "Recurrent Esophageal Cancer", "Recurrent Gastric Cancer", "Squamous Cell Carcinoma of the Esophagus", "Stage III Esophageal Cancer", "Stage IIIA Gastric Cancer", "Stage IIIB Gastric Cancer", "Stage IIIC Gastric Cancer", "Stage IV Esophageal Cancer", "Stage IV Gastric Cancer" ], "interventions": [ { "name": "oblimersen sodium", "type": "BIOLOGICAL" }, { "name": "cisplatin", "type": "DRUG" }, { "name": "fluorouracil", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "19 Years", "maximum_age": null, "sex": "ALL", "summary": "19 Years and older" }, "enrollment_count": 15, "start_date": "2003-06", "completion_date": "2010-02", "has_results": true, "last_update_posted_date": "2021-02-17", "last_synced_at": "2026-10-15T18:21:22.395Z", "location_count": 1, "location_summary": "The Bronx, New York", "locations": [ { "city": "The Bronx", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00064259" }, { "nct_id": "NCT02454179", "title": "Study of the Combination of Acalabrutinib (ACP-196) and Pembrolizumab in Advanced Head and Neck Squamous Cell Carcinoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Squamous Cell Carcinoma of the Head and Neck" ], "interventions": [ { "name": "pembrolizumab", "type": "DRUG" }, { "name": "Acalabrutinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Acerta Pharma BV", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 78, "start_date": "2015-05", "completion_date": "2018-07", "has_results": true, "last_update_posted_date": "2019-09-12", "last_synced_at": "2026-10-15T18:21:22.395Z", "location_count": 1, "location_summary": "Portland, Oregon", "locations": [ { "city": "Portland", "state": "Oregon" } ], "official_url": "https://clinicaltrials.gov/study/NCT02454179" }, { "nct_id": "NCT00003251", "title": "Amifostine Plus Chemotherapy and Radiation Therapy in Treating Patients With Advanced, Unresectable Head and Neck Cancer", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Drug/Agent Toxicity by Tissue/Organ", "Head and Neck Cancer", "Radiation Toxicity" ], "interventions": [ { "name": "amifostine trihydrate", "type": "DRUG" }, { "name": "cisplatin", "type": "DRUG" }, { "name": "paclitaxel", "type": "DRUG" }, { "name": "radiation therapy", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "University of Illinois at Chicago", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 46, "start_date": "1997-12", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-12-04", "last_synced_at": "2026-10-15T18:21:22.395Z", "location_count": 1, "location_summary": "Chicago, Illinois", "locations": [ { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT00003251" }, { "nct_id": "NCT05419089", "title": "The Sinai Robotic Surgery Trial in HPV-related Oropharyngeal Squamous Cell Carcinoma (SIRS 2.0 Trial)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "HPV-positive Oropharyngeal Squamous Cell Carcinoma" ], "interventions": [ { "name": "Robotic surgery", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE" ], "sponsor": "Icahn School of Medicine at Mount Sinai", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 83, "start_date": "2022-07-12", "completion_date": "2029-06", "has_results": false, "last_update_posted_date": "2026-07-22", "last_synced_at": "2026-10-15T18:21:22.395Z", "location_count": 2, "location_summary": "Paramus, New Jersey • New York, New York", "locations": [ { "city": "Paramus", "state": "New Jersey" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT05419089" }, { "nct_id": "NCT04152018", "title": "Study of PF-06940434 in Patients With Advanced or Metastatic Solid Tumors.", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Squamous Cell Carcinoma of the Head and Neck", "Renal Cell Carcinoma", "Ovarian Cancer", "Gastric Cancer", "Esophageal Cancer", "Lung Squamous Cell Carcinoma", "Pancreatic Cancer", "Bile Duct Cancer", "Endometrial Cancer", "Melanoma Cancer", "Urothelial Cancer" ], "interventions": [ { "name": "PF-06940434", "type": "DRUG" }, { "name": "PF-06801591", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 85, "start_date": "2019-11-13", "completion_date": "2024-12-10", "has_results": false, "last_update_posted_date": "2025-05-28", "last_synced_at": "2026-10-15T18:21:22.395Z", "location_count": 18, "location_summary": "Scottsdale, Arizona • Los Angeles, California • Santa Monica, California + 9 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Santa Monica", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04152018" }, { "nct_id": "NCT02031250", "title": "Randomized Phase II Study of DCE-MRI-based Dose Escalation for Poor-prognosis and Neck Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Squamous Cell Carcinoma of the Head and Neck" ], "interventions": [ { "name": "Cisplatin", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "IMRT (Intensity-Modulated Radiation Therapy)", "type": "RADIATION" }, { "name": "Boost Radiation to Hypoperfused Volumes", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "University of Michigan Rogel Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 106, "start_date": "2014-02", "completion_date": "2023-02-22", "has_results": true, "last_update_posted_date": "2026-03-02", "last_synced_at": "2026-10-15T18:21:22.395Z", "location_count": 2, "location_summary": "Ann Arbor, Michigan", "locations": [ { "city": "Ann Arbor", "state": "Michigan" }, { "city": "Ann Arbor", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT02031250" } ] }